Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Millennium Management LLC lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 75.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 829,885 shares of the biopharmaceutical company’s stock after selling 2,573,645 shares during the quarter. Millennium Management LLC owned approximately 0.42% of Esperion Therapeutics worth $1,826,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. SG Americas Securities LLC increased its position in Esperion Therapeutics by 96.6% in the 4th quarter. SG Americas Securities LLC now owns 151,482 shares of the biopharmaceutical company’s stock valued at $333,000 after acquiring an additional 74,433 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Esperion Therapeutics in the 4th quarter valued at about $92,000. J.W. Cole Advisors Inc. acquired a new stake in Esperion Therapeutics in the 4th quarter valued at about $66,000. Sigma Planning Corp increased its position in Esperion Therapeutics by 1,455.8% in the 4th quarter. Sigma Planning Corp now owns 190,441 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 178,200 shares in the last quarter. Finally, Summit Wealth Group LLC increased its position in Esperion Therapeutics by 292.5% in the 4th quarter. Summit Wealth Group LLC now owns 157,000 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 117,000 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Friday, April 25th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group lowered their price target on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Finally, Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.25.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $0.92 on Tuesday. The company’s 50 day simple moving average is $0.99 and its 200 day simple moving average is $1.73. Esperion Therapeutics, Inc. has a fifty-two week low of $0.69 and a fifty-two week high of $3.94. The firm has a market capitalization of $182.07 million, a price-to-earnings ratio of -1.44 and a beta of 0.75.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million. As a group, analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.